NHS braces for operational strain from doctor strikes and heatwave, while FDA approves pediatric CGM and new cancer therapies advance treatment options.

NHS faces 'triple whammy' of pressure from striking resident doctors, predicted heatwave, and England's World Cup match, creating significant operational challenges for the healthcare system during peak demand periods.

FDA extended Dexcom's Stelo continuous glucose monitoring system approval to children as young as 2 years old, expanding access to over-the-counter CGM technology for pediatric diabetes management.

LITESPARK-022 trial shows belzutifan plus pembrolizumab combination therapy reduces disease recurrence or death risk by 28% in adjuvant renal cell carcinoma treatment, offering new hope for cancer patients.

Novel oral GLP-1 medication demonstrates significant A1c reduction and weight-loss benefits without requiring fasting or fluid restrictions, providing clinicians with more flexible treatment options for diabetes management.

Medical residency competition reaches unprecedented levels, with specialties experiencing significant shifts in competitiveness and highlighting disparities in training opportunity accessibility.

Psoriasis workup increasingly expanding beyond skin and joint manifestations to address associated cardiovascular disease risks and other systemic pathologies, improving comprehensive patient care.

Chemotherapy-free treatment regimen demonstrates safety and efficacy in pediatric acute promyelocytic leukemia across both standard-risk and high-risk patient populations, advancing gentler therapeutic options.

Racial bias in medicine documented to cause delayed diagnoses and unequal pain treatment, revealing systemic healthcare disparities that clinicians may unknowingly perpetuate in patient care delivery.